There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LAG-3


Here comes a serial of ready-to-use universal ELISA kits to simplify your drug R&D. Request for free sample.

LAG-3 Molecule Information

Name:Lymphocyte activation gene 3 protein
Target Synonym:sLAG-3,Lymphocyte activation gene 3 protein,LAG3,Lymphocyte Activating 3,Lymphocyte-Activation Gene 3,CD223 Antigen,Protein FDC,CD223,LAG-3,FDC
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Phase 3 Clinical

LAG-3 Protein Product ListCompare or Buy

LAG-3 Part of Bioactivity data

LA3-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) can bind to daudi cell surface. The concentration of LAG-3 used is 0.3 μg/mL (Routinely tested).

LA3-H52Aa-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Human LAG3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) can bind to daudi cell surface. The concentration of LAG3 used is 0.3 μg/mL (Routinely tested).


Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Loaded Anti-LAG-3 MAb (Human IgG1) on AHC Biosensor, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 7.47 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

LAG-3 Customer Reviews

LAG-3 Molecule Synonym Name


LAG-3 Molecule Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

LAG-3 References

LAG-3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Fianlimab REGN-3767 Phase 1 Clinical Regeneron Pharmaceuticals Inc Neoplasms Details
IBI-110 IBI-110 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms Details
FS 118 FS-118 Phase 1 Clinical Merck Serono, F-Star Hematologic Neoplasms; Neoplasm Metastasis Details
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Stomach Neoplasms; Melanoma Details
Ieramilimab IMP-701; LAG-525 Phase 2 Clinical Immutep Ovarian Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Neuroendocrine Tumors; Sarcoma; Prostatic Neoplasms; Esophageal adenocarcinoma; Melanoma; Persistent Fetal Circulation Syndrome; Adenocarcinoma Details
XmAb-22841 XmAb-22841 Phase 1 Clinical Xencor Prostatic Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Microsatellite Instability; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell Details
TSR-033 TSR-033; TSR 033; TSR033; GSK-4074386 Phase 1 Clinical Anaptysbio Neoplasms Details
SHR-1802 SHR-1802 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours Details
IBI-323 IBI323; IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
INCAGN-2385 INCAGN-2385; INCAGN-02385 Phase 2 Clinical Agenus Inc Melanoma Details
MK-4280A MK-4280A Phase 1 Clinical Moshadong R & D (China) Co Ltd, Msd Ireland (Carlow) Merck Sharp & Dohme Corp Solid tumours Details
GSK-2831781 IMP-731; GSK‘-781; GSK-2831781; ImmuTune-IMP731 Phase 2 Clinical Prima Biomed Psoriasis; Colitis, Ulcerative Details
LBL-007 LBL-007 Phase 1 Clinical Solid tumours; Lymphoma; Melanoma Details
Chlorogenic acid Phase 3 Clinical Sichuan Jiuzhang Biological & Chemical Technology Development Co Ltd Liver Neoplasms; Kidney Neoplasms; Glioblastoma; Adenocarcinoma of Lung; Glioma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular Details
BI-754111 BI-754111 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Head and Neck Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
RO-7247669 RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MK-4280 MK-4280 Phase 2 Clinical Merck Sharp & Dohme Corp Lymphoma, B-Cell; Hematologic Neoplasms; Carcinoma, Renal Cell; Hodgkin Disease; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung Details
Sym-022 Sym-022 Phase 1 Clinical Symphogen Solid tumours; Lymphoma; Neoplasm Metastasis Details
Relatlimab ONO-4482; BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Hematologic Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Large intestine neoplasm Details
EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
DNV-3 DNV-3; DNV3 Phase 1 Clinical Zhejiang Shimai Pharmaceutical Co Ltd Solid tumours; Lymphoma Details

This web search service is supported by Google Inc.